Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9126685 | 0.90 | ABCG2 (0.35) | AHR | |
| SCHEMBL931274 | 0.79 | KDM4E (0.31) | KDM4EMAPK1ATM | |
| SCHEMBL887329 | 0.76 | KDM4E (0.34) | KDM4EMAPK1ATMHSP90AA1PKM | |
| SCHEMBL9848180 | 0.76 | HSP90AA1 (0.38) | KDM4EMAPK1ATMHSP90AA1PKM | |
| SCHEMBL14901051 | 0.76 | KDM4E (0.34) | KDM4EMAPK1ATMHSP90AA1PKM | |
| SCHEMBL11336478 | 0.71 | KDM4E (0.31) | KDM4EMAPK1ATMHSP90AA1 | |
| SCHEMBL24119839 | 0.70 | TDP1 (0.38) | KDM4EMAPK1ATMHSP90AA1PKM | |
| SCHEMBL21772799 | 0.70 | TDP1 (0.38) | KDM4EMAPK1ATMHSP90AA1PKM | |
| SCHEMBL930972 | 0.70 | KDM4E (0.31) | KDM4EMAPK1ATM | |
| SCHEMBL930294 | 0.70 | KDM4E (0.34) | KDM4EMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883765-B2 | Anti-cytomegalovirus activity of artemisinin-derived dimers | THE JOHN HOPKINS UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883765-B2 | Anti-cytomegalovirus activity of artemisinin-derived dimers | THE JOHN HOPKINS UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130109654-A1 | ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109654-A1 | ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109654-A1 | ANTI-CYTOMEGALOVIRUS ACTIVITY OF ARTEMISININ-DERIVED DIMERS | EIF2AK2, MAVS, PARP16 | KDM4E 4504/4885MAPK1 2717/4885ATM 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.